Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Group Calls for Compulsory Licensing Policy (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Jiraporn Limpananont, faculty member of the Pharmaceutical Sciences division of Chulalongkorn University in Thailand, voiced concern recently over the new government and compulsory licensing's future in Thailand following the next general election. "The new government must consider compulsory licensing to be included in the national policy and must have the intention to realize it," he stated. Thailand started dispensing compulsory licensing in late 2006. The pharmaceutical firms are Merck's MSD (Thailand), Abbott Laboratories, and Sanofi-Aventis, which make Efavirenz, Kaletra, and Plavix, respectively. Efavirenz and Kaletra are AIDS medications and Plavix is employed to combat heart disease. Achara Eksaengsri, deputy director of the Government Pharmaceutical Organization's Research and Development Institute, noted it would be simple for the new government to decree compulsory licensing for the new medications because the ministry had succeeded in utilizing compulsory licensing for heart disease pharmaceuticals and could import less expensive versions. National Research Council of Thailand's Chemical and Pharmaceutical Science research group chairman Montri Chulavatnatol stressed that the government has to think about the future of medications and the healthcare system after compulsory licensing runs out. (Print Edition Only: Link to Full Text Unavailable



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts